Evidence map›Paper›PMID 34857397›Full record

Trial reportGynecologic oncology2022

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.

Nefertiti C duPont, Danielle Enserro, Mark F Brady, Katherine Moxley, Joan L Walker, Casey Cosgrove, Kristin Bixel, Krishnansu S Tewari, Premal Thaker, Andrea E Wahner Hendrickson and 6 more

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 2 countries.

Nefertiti C duPontNorth Houston Gynecologic Oncology Surgeons, Shenandoah, TX, USA. Electronic address: ndupont@gynonchouston.com.
Danielle EnserroNRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: enserrod@nrgoncology.org.
Mark F BradyNRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: bradym@nrgoncology.org.
Katherine MoxleyUniversity of Oklahoma, Oklahoma University Hospital Science Center, Oklahoma City, OK 73104, USA. Electronic address: Katherine-moxley@ouhsc.edu.
Joan L WalkerUniversity of Oklahoma, Oklahoma University Hospital Science Center, Oklahoma City, OK 73104, USA. Electronic address: Joan-walker@ouhsc.edu.
Casey CosgroveOhio State University Medical Center, USA. Electronic address: Casey.cosgrove@osumc.edu.
Kristin BixelOhio State University Medical Center, USA. Electronic address: Kristin.Bixel@osumc.edu.
Krishnansu S TewariUniversity of California at Irvine, Orange, CA 92868, USA. Electronic address: ktewari@uci.edu.
Premal ThakerWashington University, Saint Louis, MO 63110, USA. Electronic address: thakerp@wustl.edu.
Andrea E Wahner HendricksonMayo Clinic, Rochester, MN 55905, USA. Electronic address: WahnerHendrickson.Andrea@mayo.edu.
Stephen RubinAbramson Cancer Center at University of Pennsylvania, Philadelphia, PA 19111, USA. Electronic address: Stephen.rubin@fccc.edu.
Keiichi FujiwaraSaitama Medical University/International Medical Center, Saitama, JP 350-1298, Japan. Electronic address: fujiwara@saitama-med.ac.jp.
A Catherine CaseyMetro Minn CCOP, Minneapolis, MN, USA. Electronic address: acatherine.casey@usoncology.com.
John SoperUniversity of North Carolina, Chapel Hill, NC 27599, USA. Electronic address: john_soper@med.unc.edu.
Robert A BurgerDivision of Gynecologic Oncology, Arizona Oncology (US Oncology Network), Phoenix, AZ, USA. Electronic address: Bob@xonehorse.com.
Bradley J MonkUniversity of Arizona College of Medicine, Phoenix Creighton University School of Medicine at St. Joseph's Hospital, Phoenix, AZ, USA. Electronic address: Bradley.Monk@usoncology.com.
Creighton University · USMayo Clinic in Arizona · USNRG Oncology · USOklahoma City University · USRoswell Park Comprehensive Cancer Center · USSaitama International Medical Center · JPThe Ohio State University · USThe Ohio State University Wexner Medical Center · USThe US Oncology Network · USUniversity of North Carolina at Chapel Hill · USUniversity of Oklahoma · USUniversity of Pennsylvania · USWashington University in St. Louis · US

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4M
Network Lead Academic Participating Site Grant from the Roswell Park Cancer InstituteUG1CA233191 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI LELE, SHASHIKANT, LEVINE, ELLIS G · 2019 to 2025
$3.1M
NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA233191
6 · The paper itself

Abstract

backgroundAge and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy.

methodsWomen with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants.

resultsOne-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90).

conclusionsNon-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.

Indexed as

AdenocarcinomaAgedAged, 80 and overAge FactorsAngiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAsianBevacizumabBlack or African AmericanCarboplatinCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialChemotherapy, AdjuvantEthnicityFallopian Tube NeoplasmsFemaleAngiogenesis InhibitorsBevacizumabCarboplatinPaclitaxelAfrican American womenAsian womenBevacizumabElderlyMinority populationsOvarian cancer

Identifiers

PMID34857397
PMCPMC9400113
OpenAlexW3217748527

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.